Does statin use improve pneumonia outcomes?

Despite medical advances, pneumonia remains a leading cause of morbidity and mortality among patients in developed countries. It is therefore not surprising that much research has been devoted to improving outcomes associated with this condition. Traditionally thought of as lipid-lowering agents, the 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (hereafter referred to as statins) have "pleiotropic" effects of clinical relevance. Several studies have reported an association between statin use and improved health outcomes, including those associated with pneumonia. While many of these are limited by their retrospective or observational methodology, the finding that statin use may improve pneumonia outcomes is tantalizing and worthy of further exploration. Our review of the literature found several potential mechanisms by which statins could influence the course of bacterial pneumonia. For instance, statins directly attenuate inflammation and inflammatory markers, are antioxidative and immunomodulatory, and exert in vitro antibacterial effects on microbial pathogens. On the other hand, statin use is also thought to be a surrogate marker for better health and may simply be a confounding variable when it comes to pneumonia. This article explores some of the potential mechanisms by which statin therapy may impact the course of pneumonia. In addition, we review the clinical studies both supporting and arguing against such an effect.

[1]  B. Skipper,et al.  Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. , 2007, Chest.

[2]  J. Emmersen,et al.  Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. , 2009, The Journal of antimicrobial chemotherapy.

[3]  A. Giusti-Paiva,et al.  Simvastatin Decreases Nitric Oxide Overproduction and Reverts the Impaired Vascular Responsiveness Induced by Endotoxic Shock in Rats , 2004, Shock.

[4]  R. Paterson.  Prior Statin Use is Associated with Improved Outcomes in Community-Acquired Pneumonia , 2009 .

[5]  P. Gandhi,et al.  HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  P. Pronovost,et al.  Public Reporting of Antibiotic Timing in Patients with Pneumonia: Lessons from a Flawed Performance Measure , 2008, Annals of Internal Medicine.

[7]  V. Chopra,et al.  Beyond Lipid Lowering: The Anti-Hypertensive Role of Statins , 2007, Cardiovascular Drugs and Therapy.

[8]  S. O’Neill,et al.  Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. , 1999, Thorax.

[9]  M. Salmona,et al.  In Vivo Anti-Inflammatory Effect of Statins Is Mediated by Nonsterol Mevalonate Products , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[10]  S. Corbett,et al.  Simvastatin suppresses LPS-induced Akt phosphorylation in the human monocyte cell line THP-1. , 2004, The Journal of surgical research.

[11]  J. Cohen,et al.  Unexpected antimicrobial effect of statins. , 2007, The Journal of antimicrobial chemotherapy.

[12]  W. Erl,et al.  HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. , 1997, Journal of the American College of Cardiology.

[13]  H. Katus,et al.  Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. , 2000, Circulation.

[14]  K. Erdmann,et al.  Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. , 2004, Biochemical and biophysical research communications.

[15]  A. Anzueto,et al.  Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia , 2008, European Respiratory Journal.

[16]  R. Schlienger,et al.  Statins and the Risk of Pneumonia: A Population‐Based, Nested Case‐Control Study , 2007, Pharmacotherapy.

[17]  J. Nick,et al.  A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense. , 2005, American journal of respiratory and critical care medicine.

[18]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[19]  B. Naidu,et al.  Simvastatin ameliorates injury in an experimental model of lung ischemia-reperfusion. , 2003, The Journal of thoracic and cardiovascular surgery.

[20]  U. Laufs,et al.  Isoprenoid metabolism and the pleiotropic effects of statins , 2003, Current atherosclerosis reports.

[21]  D. Menon,et al.  Plasma antioxidant potential in severe sepsis: a comparison of survivors and nonsurvivors. , 1996, Critical care medicine.

[22]  P. Howdle,et al.  Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. , 1995, Critical care medicine.

[23]  H. Ogawa,et al.  Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndrome , 2003, Critical care medicine.

[24]  A. M. Lefer,et al.  Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[25]  H. Bøggild,et al.  Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. , 2005, British journal of clinical pharmacology.

[26]  F. McAlister,et al.  Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study , 2006, BMJ : British Medical Journal.

[27]  G. Patti,et al.  Simvastatin attenuates leucocyte–endothelial interactions after coronary revascularisation with cardiopulmonary bypass , 2003, Heart.

[28]  A. Frew,et al.  Systemic cytokine levels in community-acquired pneumonia and their association with disease severity , 2002, European Respiratory Journal.

[29]  R. Rosenson,et al.  Statins and sepsis: multiple modifications at multiple levels. , 2007, The Lancet. Infectious diseases.

[30]  A. Anzueto,et al.  The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia , 2005, Respiratory research.

[31]  R. de Caterina,et al.  Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts* , 2005, Journal of Biological Chemistry.

[32]  Joerg Kallen,et al.  Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site , 2001, Nature Medicine.

[33]  A. Hoes,et al.  Statin treatment and reduced risk of pneumonia in patients with diabetes , 2006, Thorax.

[34]  Mark Jones,et al.  Statin therapy is associated with fewer deaths in patients with bacteraemia , 2005, Intensive Care Medicine.

[35]  F. Mach,et al.  Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. , 2006, Atherosclerosis.

[36]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[37]  R. Kriwacki,et al.  Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. , 1999, Journal of molecular biology.

[38]  C. McDonald,et al.  Rising incidence and persistently high mortality of hospitalized pneumonia: a 10‐year population‐based study in Denmark , 2006, Journal of internal medicine.

[39]  H. Joller-jemelka,et al.  Statin-induced immunomodulatory effects on human T cells in vivo. , 2004, Atherosclerosis.

[40]  D. Grigoryev,et al.  Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. , 2005, American journal of physiology. Lung cellular and molecular physiology.

[41]  Sebastian Schneeweiss,et al.  Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. , 2006, Journal of clinical epidemiology.

[42]  Steffen Christensen,et al.  Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. , 2008, Archives of internal medicine.

[43]  R. Holman,et al.  Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. , 2005, JAMA.

[44]  F. Brunner‐Ferber,et al.  Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans , 1992, Journal of clinical pharmacology.

[45]  Francesco Saverio Tedesco,et al.  Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement‐mediated acute inflammation , 2004, Clinical and experimental immunology.

[46]  H. M. Soliman,et al.  C-reactive protein levels correlate with mortality and organ failure in critically ill patients. , 2003, Chest.

[47]  A. Hill,et al.  C-reactive protein is an independent predictor of severity in community-acquired pneumonia. , 2008, The American journal of medicine.